{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/6a3bd899eeb75ff76e15886e?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? ","description":"<p>During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? </p><p><br></p><p>This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}